We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.
- Authors
Yap, Timothy A; Olmos, David; Brunetto, Andre T; Tunariu, Nina; Barriuso, Jorge; Riisnaes, Ruth; Pope, Lorna; Clark, Jeremy; Futreal, Andrew; Germuska, Michael; Collins, David; deSouza, Nandita M; Leach, Martin O; Savage, Ronald E; Waghorne, Carol; Chai, Feng; Garmey, Edward; Schwartz, Brian; Kaye, Stan B; de Bono, Johann S
- Abstract
The hepatocyte growth factor/c-MET axis is implicated in tumor cell proliferation, survival, and angiogenesis. ARQ 197 is an oral, selective, non-adenosine triphosphate competitive c-MET inhibitor. A phase I trial of ARQ 197 was conducted to assess safety, tolerability, and target inhibition, including intratumoral c-MET signaling, apoptosis, and angiogenesis.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 10, p1271
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.31.0367